Efficacy and safety of EGFR-TKIs for non-small cell lung cancer: A meta-analysis of randomized controlled clinical trials
Xiaoming Lai,Jinlin Zeng,Zhijun Xiao,Junlan Xiao
DOI: https://doi.org/10.1097/md.0000000000038277
IF: 1.6
2024-06-09
Medicine
Abstract:Worldwide, lung cancer is the leading cause of cancer-related deaths among people of all ages. [ 1 ] As the leading cause of cancer-related deaths worldwide, lung cancer poses a significant threat to human health, and it is estimated that nearly 1.4 million people die from lung cancer every year. Due to the many concomitant medical conditions associated with localized disease, it continues to be difficult for a substantial proportion of patients to undergo curative resection procedures in order to cure their cancer. [ 2 ] In many cases, patients suffer from advanced stages of the disease when they are diagnosed. This is the primary cause of the high mortality rate associated with this disease. According to current chemotherapy options, such as platinum-based therapy, there seems to have been a plateau in the efficacy of current chemotherapy options. [ 3 ] A common genomic alteration in non-small cell lung cancer (NSCLC) is the presence of mutations that sensitize the epidermal growth factor receptor (EGFR) gene. Approximately 15% of lung adenocarcinomas in the United States and 22% to 64% of lung adenocarcinomas in Asian patients exhibit these markers. [ 4 ] As a result of the recent development of efficient EGFR tyrosine kinase inhibitors (TKIs), there are now 5 different agents that can be used to treat advanced NSCLC with common EGFR-sensitizing mutations available on the market: erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib. There are several types of TKIs that are available on the market today, including 1st-generation, 2nd-generation, and 3rd-generation agents. Afatinib and osimertinib, 2 TKIs of the 3rd-generation and 2nd-generation, respectively, have shown some persistent activity in the treatment of some uncommon mutations in the EGFR. [ 5 ] There have been a series of studies examining the efficacy of EGFR-TKIs as an adjuvant treatment for resected NSCLC due to their improvement in response rates and a significantly enhanced survival rate compared to doublet chemotherapy in advanced NSCLC. [ 6 ] In spite of this, subsequent randomized controlled trials (RCTs) gave contradictory results when compared to placebo treatment or adjuvant chemotherapy for patients with operable NSCLC in which EGFR-TKIs were used at adjuvant stages, suggesting that adjuvant treatment could improve the prognosis for patients with operable NSCLC. [ 6 ]
medicine, general & internal